Journal Publications

2020


2019


- de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C,


2018


- Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA,
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2017

- Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein NL, Kaizer L,


- Lipton A, Chapman JA, Leitzel K, Garg A, Pritchard KL, Ingle JN, Budd GT, Ellis MJ,


2016


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JA, Chen BE, Kubo M,

- Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


- Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski


2015

- Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. Lung Cancer 90:
288-95, 2015.


2014

- Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, Jurisica I, Shepherd FA, Tsao


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.


- Wu AW, Bradford AN, Velanovich V, Sprangers MAG, Brundage M, Snyder C. Clinician's Checklist for Reading and Using an Article About Patient-Reported

2013


Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang


- Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R,


Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.


• Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AMK, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer Genomics:


2011

- Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue


- Kouroukis CT, Fernandez LAV, Crump M, Chua NS, Buckstein R, Turner R, Assouline


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.


- Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, Flechtner H,


- Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adenoc colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


- Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J,


- Wheatley-Price P, Le Maître A, Ding K, Leigh N, Hirsh V, Seymour L, Bezjak A,


2009


- Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC

- Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ,


2007

Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J,


- Pritchard KL, Shepherd LE, O'Malley FP, Andreulis I, Andreulis IL, Tu D, Bramwell VH,


- Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


2005


- Chen Y. Long-term quality of life assessment in post-menopausal women with primary
breast cancer, 2005. Queen's University, Dept of Community Health & Epidemiology (Thesis).


- Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. A phase I study of T900607 given once every 3 weeks in patients...


2003

• Ding K. A lower confidence bound for the change point after a sequential CUSUM test.


Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel...


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2001


2000


1999

- James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P.

- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.


1997

Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.


• Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.
• Eisenhauer E. The role of paclitaxel in ovarian cancer treatment. Oncology and Hematology 4: 7-9, 1996.
• Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J,


1995


- Eisenhauer E, Trudeau M. An overview of phase II studies of docetaxel in patients with

1994

- Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and


1993


1992


1991


• Monga M, Carmichael J, Shelley W, Kirk M, Krepart G, Jeffrey JF, Pater J. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after...

1990

• Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Activity of intravenous


1989


1988


1987


1986


Eisenhauer E, Quirt I, Connors JM, Maroun J, Skillings J. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An


1984

1980


1979